Latest Insider Transactions at Iterum Therapeutics PLC (ITRM)
This section provides a real-time view of insider transactions for Iterum Therapeutics PLC (ITRM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Iterum Therapeutics plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Iterum Therapeutics plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 26
2021
|
Judith M. Matthews Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
33,868
-54.19%
|
$33,868
$1.73 P/Share
|
|
Jan 26
2021
|
Michael W. Dunne |
SELL
Open market or private sale
|
Direct |
33,143
-11.45%
|
$33,143
$1.73 P/Share
|
|
Jan 26
2021
|
Corey N. Fishman Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
85,445
-20.97%
|
$85,445
$1.73 P/Share
|
|
Jan 25
2021
|
Judith M. Matthews Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+50.0%
|
-
|
|
Jan 25
2021
|
Michael W. Dunne |
BUY
Grant, award, or other acquisition
|
Direct |
80,000
+21.65%
|
-
|
|
Jan 25
2021
|
Corey N. Fishman Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
167,500
+29.13%
|
-
|
|
Oct 27
2020
|
Michael W. Dunne |
BUY
Open market or private purchase
|
Direct |
61,540
+22.71%
|
-
|
|
Sep 30
2020
|
Judith M. Matthews Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
56,130
-100.0%
|
$56,130
$1.64 P/Share
|
|
Jul 28
2020
|
Mark Chin Director |
SELL
Other acquisition or disposition
|
Direct |
11,857
-100.0%
|
-
|
|
May 30
2018
|
Canaan X L.P. Director |
BUY
Open market or private purchase
|
Direct |
506,656
+22.62%
|
$6,586,528
$13.0 P/Share
|
|
May 30
2018
|
Canaan X L.P. Director |
BUY
Conversion of derivative security
|
Direct |
1,226,514
+29.14%
|
-
|